Leoni LM (2008). “Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.”. Clin Cancer Res.14 (1): 309-17. doi:10.1158/1078-0432.CCR-07-1061.. PMID18172283.
Roué G (2008). “Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.”. Clin Cancer Res.14 (21): 6907-15. doi:10.1158/1078-0432.CCR-08-0388.. PMID18980985.
Strumberg D (1996). “Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.”. Anticancer Drugs.7 (4): 415-21. PMID8826610.
Leoni LM (2008). “Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.”. Clin Cancer Res.14 (1): 309-17. doi:10.1158/1078-0432.CCR-07-1061.. PMID18172283.
Roué G (2008). “Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.”. Clin Cancer Res.14 (21): 6907-15. doi:10.1158/1078-0432.CCR-08-0388.. PMID18980985.